1805 related articles for article (PubMed ID: 26209535)
61. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
Dosouto C; Haahr T; Humaidan P
Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
[TBL] [Abstract][Full Text] [Related]
62. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
Herman A; Raziel A; Strassburger D; Soffer Y; Bukovsky I; Ron-El R
Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
[TBL] [Abstract][Full Text] [Related]
63. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
[TBL] [Abstract][Full Text] [Related]
64. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
65. GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis.
Haahr T; Roque M; Esteves SC; Humaidan P
Front Endocrinol (Lausanne); 2017; 8():116. PubMed ID: 28638367
[TBL] [Abstract][Full Text] [Related]
66. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
67. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
[TBL] [Abstract][Full Text] [Related]
68. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
[TBL] [Abstract][Full Text] [Related]
69. The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients.
Humaidan P; Alsbjerg B; Elbaek HO; Povlsen BB; Laursen RJ; Jensen MB; Mikkelsen AT; Thomsen LH; Kol S; Haahr T
Reprod Biomed Online; 2021 Jun; 42(6):1108-1118. PubMed ID: 33931371
[TBL] [Abstract][Full Text] [Related]
70. Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience.
Andersen CY; Fischer R; Giorgione V; Kelsey TW
J Assist Reprod Genet; 2016 Oct; 33(10):1311-1318. PubMed ID: 27448021
[TBL] [Abstract][Full Text] [Related]
71. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
72. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
73. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
Fatemi HM; Camus M; Kolibianakis EM; Tournaye H; Papanikolaou EG; Donoso P; Devroey P
Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
[TBL] [Abstract][Full Text] [Related]
74. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
[TBL] [Abstract][Full Text] [Related]
75. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
[TBL] [Abstract][Full Text] [Related]
76. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
[TBL] [Abstract][Full Text] [Related]
77. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
[TBL] [Abstract][Full Text] [Related]
78. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization.
Baker VL; Jones CA; Doody K; Foulk R; Yee B; Adamson GD; Cometti B; DeVane G; Hubert G; Trevisan S; Hoehler F; Jones C; Soules M
Hum Reprod; 2014 Oct; 29(10):2212-20. PubMed ID: 25100106
[TBL] [Abstract][Full Text] [Related]
79. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.
von Wolff M; Kollmann Z; Flück CE; Stute P; Marti U; Weiss B; Bersinger NA
Hum Reprod; 2014 May; 29(5):1049-57. PubMed ID: 24608520
[TBL] [Abstract][Full Text] [Related]
80. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
